<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font23 { font-size : 23; } .font26 { font-size : 26; } .font29 { font-size : 29; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">migraine </span>
   <span class="font29">women </span>
   <span class="font26">headache </span>
   <span class="font23">treatment </span>
   <span class="font23">study </span>
   <span class="font20">days </span>
   <span class="font19">estradiol </span>
   <span class="font18">use </span>
   <span class="font17">oral </span>
   <span class="font17">studies </span>
   <span class="font17">evidence </span>
   <span class="font16">Headache </span>
   <span class="font15">supplementation </span>
   <span class="font15">estrogen </span>
   <span class="font15">patch </span>
   <span class="font15">associated </span>
   <span class="font15">aura </span>
   <span class="font14">attacks </span>
   <span class="font14">menstrual </span>
   <span class="font14">performed </span>
   <span class="font14">reported </span>
   <span class="font14">pill-free </span>
   <span class="font14">regimen </span>
   <span class="font14">combined </span>
   <span class="font14">contraception </span>
   <span class="font14">contraceptives </span>
   <span class="font14">desogestrel </span>
   <span class="font14">observational </span>
   <span class="font14">related </span>
   <span class="font14">number </span>
   <span class="font13">compared </span>
   <span class="font13">cycle </span>
   <span class="font13">hormonal </span>
   <span class="font13">Table </span>
   <span class="font13">Women </span>
   <span class="font13">cycles </span>
   <span class="font13">placebo </span>
   <span class="font13">quality </span>
   <span class="font13">extended </span>
   <span class="font13">transdermal </span>
   <span class="font13">according </span>
   <span class="font13">contraceptive </span>
   <span class="font13">medical </span>
   <span class="font13">specifically </span>
   <span class="font13">interval </span>
   <span class="font13">pill </span>
   <span class="font13">reduction </span>
   <span class="font13">CHCs </span>
   <span class="font13">Weak </span>
   <span class="font13">diagnosis </span>
   <span class="font13">μg/day </span>
   <span class="font12">Migraine </span>
   <span class="font12">available </span>
   <span class="font12">data </span>
   <span class="font12">duration </span>
   <span class="font12">menstruation </span>
   <span class="font12">reasons </span>
   <span class="font12">severity </span>
   <span class="font12">[], </span>
   <span class="font12">patients </span>
   <span class="font12">CHC </span>
   <span class="font12">ICHD- </span>
   <span class="font12">benefits </span>
   <span class="font12">included </span>
   <span class="font12">migraine, </span>
   <span class="font12">criteria </span>
   <span class="font12">criteria. </span>
   <span class="font12">pain </span>
   <span class="font12">suggested </span>
   <span class="font12">{border-style </span>
   <span class="font12">PMM </span>
   <span class="font12">low </span>
   <span class="font12">observation </span>
   <span class="font12">treated </span>
   <span class="font12">estrogens </span>
   <span class="font12">gel </span>
   <span class="font12">months </span>
   <span class="font12">px;} </span>
   <span class="font12">#ffffff;} </span>
   <span class="font12">(. ± . </span>
   <span class="font12">. ± .; </span>
   <span class="font12">MRM </span>
   <span class="font12">possible </span>
   <span class="font12">withdrawal </span>
   <span class="font11">Combined </span>
   <span class="font11">active </span>
   <span class="font11">exogenous </span>
   <span class="font11">intensity </span>
   <span class="font11">previous </span>
   <span class="font11">reproductive </span>
   <span class="font11">risk </span>
   <span class="font11">used </span>
   <span class="font11">(Table </span>
   <span class="font11">University </span>
   <span class="font11">. ± . </span>
   <span class="font11">Low </span>
   <span class="font11">P &amp;lt; .) </span>
   <span class="font11">fulfilling </span>
   <span class="font11">grid.. </span>
   <span class="font11">medication </span>
   <span class="font11">occurrence </span>
   <span class="font11">period </span>
   <span class="font11">rated </span>
   <span class="font11">required </span>
   <span class="font11">  A. </span>
   <span class="font11">  B. </span>
   <span class="font11">Department </span>
   <span class="font11">Estradiol </span>
   <span class="font11">Recommendations </span>
   <span class="font11">assessed </span>
   <span class="font11">considered </span>
   <span class="font11">group </span>
   <span class="font11">require </span>
   <span class="font11">ring </span>
   <span class="font11">shortened </span>
   <span class="font11">vaginal </span>
   <span class="font11">(ICHD-); </span>
   <span class="font11">Health </span>
   <span class="font11">conclusion, </span>
   <span class="font11">consensus </span>
   <span class="font11">conventional </span>
   <span class="font11">criterion </span>
   <span class="font11">did </span>
   <span class="font11">migraine. </span>
   <span class="font11">prescribed </span>
   <span class="font11">progestogen </span>
   <span class="font11">setting </span>
   <span class="font11">treatment. </span>
   <span class="font11">users </span>
   <span class="font11">Contraception </span>
   <span class="font11">Details </span>
   <span class="font11">European </span>
   <span class="font11">day </span>
   <span class="font11">dropped-out </span>
   <span class="font11">hormones </span>
   <span class="font11">implant </span>
   <span class="font11">menstruation, </span>
   <span class="font11">placebo-controlled, </span>
   <span class="font11">progestogens </span>
   <span class="font11">provide </span>
   <span class="font11">randomized, </span>
   <span class="font11">treatments </span>
   <span class="font11">(on </span>
   <span class="font11">Classification </span>
   <span class="font11">ICHD </span>
   <span class="font11">International </span>
   <span class="font11">POP </span>
   <span class="font11">P = . </span>
   <span class="font11">Society </span>
   <span class="font11">Suggested </span>
   <span class="font11">Transdermal </span>
   <span class="font11">analysis) </span>
   <span class="font11">course </span>
   <span class="font11">crossover </span>
   <span class="font11">effect </span>
   <span class="font11">hormone </span>
   <span class="font11">increase </span>
   <span class="font11">occur </span>
   <span class="font11">referring </span>
   <span class="font11">severe </span>
   <span class="font11">stroke </span>
   <span class="font11">systematic </span>
   <span class="font11">worsening </span>
   <span class="font11">However, </span>
   <span class="font11">MacGregor </span>
   <span class="font11">Morotti </span>
   <span class="font11">additional </span>
   <span class="font11">addressed </span>
   <span class="font11">analgesic </span>
   <span class="font11">attacks, </span>
   <span class="font11">current </span>
   <span class="font11">double-blind, </span>
   <span class="font11">effects </span>
   <span class="font11">menopause </span>
   <span class="font11">option </span>
   <span class="font11">significant </span>
   <span class="font11">single </span>
   <span class="font11">times </span>
   <span class="font11">    . </span>
   <span class="font10">(i.e. </span>
   <span class="font10">(–) </span>
   <span class="font10">Attacks, </span>
   <span class="font10">Pain </span>
   <span class="font10">P &amp;lt; .). </span>
   <span class="font10">P = .) </span>
   <span class="font10">Randomized, </span>
   <span class="font10">Reproductive </span>
   <span class="font10">Treatment </span>
   <span class="font10">better </span>
   <span class="font10">clinical </span>
   <span class="font10">decreased </span>
   <span class="font10">developed </span>
   <span class="font10">dose </span>
   <span class="font10">drug </span>
   <span class="font10">evaluated </span>
   <span class="font10">frequency </span>
   <span class="font10">information </span>
   <span class="font10">interventional </span>
   <span class="font10">limited </span>
   <span class="font10">limited. </span>
   <span class="font10">menstruating </span>
   <span class="font10">need </span>
   <span class="font10">onset </span>
   <span class="font10">px; </span>
   <span class="font10">score </span>
   <span class="font10">statements </span>
   <span class="font10">taking </span>
   <span class="font10">using </span>
   <span class="font10">woman, </span>
   <span class="font10">{font-family </span>
   <span class="font10"> ±  </span>
   <span class="font10">Cephalalgia </span>
   <span class="font10">Desogestrel </span>
   <span class="font10">Extended </span>
   <span class="font10">ICHD, </span>
   <span class="font10">Nappi </span>
   <span class="font10">additionally </span>
   <span class="font10">age </span>
   <span class="font10">baseline </span>
   <span class="font10">bleeding </span>
   <span class="font10">clear </span>
   <span class="font10">collab: </span>
   <span class="font10">competing </span>
   <span class="font10">days, </span>
   <span class="font10">design. </span>
   <span class="font10">difference </span>
   <span class="font10">events </span>
   <span class="font10">exclusively </span>
   <span class="font10">font-size </span>
   <span class="font10">induced </span>
   <span class="font10">ischemic </span>
   <span class="font10">management </span>
   <span class="font10">management. </span>
   <span class="font10">pharmacological </span>
   <span class="font10">plus </span>
   <span class="font10">recommendations </span>
   <span class="font10">reduced </span>
   <span class="font10">regimen. </span>
   <span class="font10">regimens </span>
   <span class="font10">resolved </span>
   <span class="font10">selected </span>
   <span class="font10">significantly </span>
   <span class="font10">statement </span>
   <span class="font10">strategies </span>
   <span class="font10">subcutaneous </span>
   <span class="font10">μg/ </span>
   <span class="font10">Allergan, </span>
   <span class="font10">Available </span>
   <span class="font10">Bayer </span>
   <span class="font10">Data </span>
   <span class="font10">GRADE </span>
   <span class="font10">MO, </span>
   <span class="font10">Sacco </span>
   <span class="font10">attacks. </span>
   <span class="font10">containing </span>
   <span class="font10">cyclical </span>
   <span class="font10">double; </span>
   <span class="font10">drugs </span>
   <span class="font10">edition </span>
   <span class="font10">edition, </span>
   <span class="font10">following: </span>
   <span class="font10">frovatriptan </span>
   <span class="font10">gynecological </span>
   <span class="font10">high </span>
   <span class="font10">impact </span>
   <span class="font10">improve </span>
   <span class="font10">improvement </span>
   <span class="font10">intensity, </span>
   <span class="font10">interests. </span>
   <span class="font10">literature </span>
   <span class="font10">month </span>
   <span class="font10">occurred </span>
   <span class="font10">panelists </span>
   <span class="font10">placebo. </span>
   <span class="font10">post-treatment </span>
   <span class="font10">progestogen-only </span>
   <span class="font10">prospective </span>
   <span class="font10">reasons. </span>
   <span class="font10">review </span>
   <span class="font10">support </span>
   <span class="font10">symptoms </span>
   <span class="font10">unrelated </span>
   <span class="font10">week </span>
   <span class="font10">weekly </span>
   <span class="font10"> .. </span>
   <span class="font10">  C. </span>
   <span class="font10">-day </span>
   <span class="font10">-month </span>
   <span class="font10">./s--- </span>
   <span class="font10">Additionally, </span>
   <span class="font10">Disorders </span>
   <span class="font10">Evidence </span>
   <span class="font10">Federation </span>
   <span class="font10">HealthCare, </span>
   <span class="font10">Lilly, </span>
   <span class="font10">Medical </span>
   <span class="font10">Merki-Feld </span>
   <span class="font10">Neurology, </span>
   <span class="font10">Prevention </span>
   <span class="font10">Pure </span>
   <span class="font10">Reduction </span>
   <span class="font10">aura, </span>
   <span class="font10">benefit </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">case </span>
   <span class="font10">classification </span>
   <span class="font10">continuous </span>
   <span class="font10">cross-over </span>
   <span class="font10">cycles. </span>
   <span class="font10">delayed </span>
   <span class="font10">different </span>
   <span class="font10">disability </span>
   <span class="font10">document </span>
   <span class="font10">duration, </span>
   <span class="font10">female </span>
   <span class="font10">followed </span>
   <span class="font10">following </span>
   <span class="font10">frequency, </span>
   <span class="font10">headaches </span>
   <span class="font10">implants </span>
   <span class="font10">increased </span>
   <span class="font10">indicate </span>
   <span class="font10">international </span>
   <span class="font10">migraine: </span>
   <span class="font10">migraine; </span>
   <span class="font10">migraines </span>
   <span class="font10">non </span>
   <span class="font10">observed </span>
   <span class="font10">open-label </span>
   <span class="font10">option. </span>
   <span class="font10">parallel </span>
   <span class="font10">patch-free </span>
   <span class="font10">patch. </span>
   <span class="font10">patches </span>
   <span class="font10">percutaneous </span>
   <span class="font10">period. </span>
   <span class="font10">pure </span>
   <span class="font10">report </span>
   <span class="font10">retrospective, </span>
   <span class="font10">role </span>
   <span class="font10">scores </span>
   <span class="font10">search </span>
   <span class="font10">severity, </span>
   <span class="font10">solid; </span>
   <span class="font10">statements. </span>
   <span class="font10">therapeutic </span>
   <span class="font10">use, </span>
   <span class="font10">vascular </span>
   <span class="font10">women. </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">  D. </span>
   <span class="font10">(days </span>
   <span class="font10">./j.-...x </span>
   <span class="font10">Amgen, </span>
   <span class="font10">Calhoun </span>
   <span class="font10">Carolei </span>
   <span class="font10">Daily </span>
   <span class="font10">Gynecol </span>
   <span class="font10">III </span>
   <span class="font10">Medicine, </span>
   <span class="font10">Menstrually </span>
   <span class="font10">Novartis, </span>
   <span class="font10">Number </span>
   <span class="font10">Obstet </span>
   <span class="font10">Occurring </span>
   <span class="font10">Progestogen-only </span>
   <span class="font10">Prospective, </span>
   <span class="font10">Quality </span>
   <span class="font10">Reduced </span>
   <span class="font10">Retrospective, </span>
   <span class="font10">Sances </span>
   <span class="font10">Study </span>
   <span class="font10">accounted </span>
   <span class="font10">adverse </span>
   <span class="font10">approval </span>
   <span class="font10">bold </span>
   <span class="font10">cardiovascular </span>
   <span class="font10">causation </span>
   <span class="font10">cessation </span>
   <span class="font10">clinic </span>
   <span class="font10">consecutive </span>
   <span class="font10">courier; </span>
   <span class="font10">cycles, </span>
   <span class="font10">daily </span>
   <span class="font10">demonstrated </span>
   <span class="font10">differences </span>
   <span class="font10">dosage </span>
   <span class="font10">draft </span>
   <span class="font10">em; </span>
   <span class="font10">estrogen-withdrawal </span>
   <span class="font10">exclusion </span>
   <span class="font10">goserelin </span>
   <span class="font10">higher </span>
   <span class="font10">hours </span>
   <span class="font10">including </span>
   <span class="font10">individual </span>
   <span class="font10">intake </span>
   <span class="font10">interval, </span>
   <span class="font10">meet </span>
   <span class="font10">menstrually-related </span>
   <span class="font10">migraineurs </span>
   <span class="font10">moderate </span>
   <span class="font10">naproxen </span>
   <span class="font10">needed </span>
   <span class="font10">new </span>
   <span class="font10">note </span>
   <span class="font10">outcome </span>
   <span class="font10">pain, </span>
   <span class="font10">patient </span>
   <span class="font10">periods </span>
   <span class="font10">pilot </span>
   <span class="font10">placebo-controlled </span>
   <span class="font10">pre- </span>
   <span class="font10">preventive </span>
   <span class="font10">provided </span>
   <span class="font10">pt;} </span>
   <span class="font10">randomized </span>
   <span class="font10">reported. </span>
   <span class="font10">reporting </span>
   <span class="font10">round </span>
   <span class="font10">specific </span>
   <span class="font10">strategy </span>
   <span class="font10">therapy </span>
   <span class="font10">trials </span>
   <span class="font10">users), </span>
   <span class="font10">version </span>
   <span class="font10">versus </span>
   <span class="font10">weeks </span>
   <span class="font10">weeks, </span>
   <span class="font10">women: </span>
   <span class="font10">young </span>
   <span class="font10">μg  drospirenone </span>
   <span class="font10"> A.. </span>
   <span class="font10"> A... </span>
  </p>
 </body>
</html>
